FIELD: medicine.
SUBSTANCE: recombinant adeno associated virus (hereinafter – rAAV) is proposed for the treatment of osteoarthritis (hereinafter – OA), containing rAAV vector with a nucleic acid sequence encoding polypeptide of canine hyaluronsintase 2 (hereinafter – HAS2) functionally connected to promotor. A pharmaceutical composition is proposed, containing the specified rAAV, as well as its use for the treatment of OA. A method is proposed for the treatment of a mammal subject suffering from OA, including intra-articular injection of therapeutically effective amount of rAAV.
EFFECT: proposed group of inventions provides for the achievement of polypeptide HAS2 expression in joint cells in vivo for the treatment of OA.
18 cl, 19 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
| ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
